Veritas In Silico Inc. (JP:130A) has released an update.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Veritas In Silico Inc. has partnered with Liverpool ChiroChem to develop mRNA-targeted small molecule drugs, aiming to create innovative therapeutics for various diseases. This strategic collaboration combines both companies’ platforms to potentially generate groundbreaking drug candidates. The agreement marks a significant step in Veritas In Silico’s growth strategy, although no immediate revenue is expected from this contract.
For further insights into JP:130A stock, check out TipRanks’ Stock Analysis page.